(Q43454599)

23 November 2017

title

Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma (English)

1 reference

23 November 2017

Koji Miyahara

1

1 reference

23 November 2017

Kazuhiro Nouso

2

1 reference

23 November 2017

Yuki Morimoto

3

1 reference

23 November 2017

Yasuto Takeuchi

4

1 reference

23 November 2017

Hiroaki Hagihara

5

1 reference

23 November 2017

Kenji Kuwaki

6

1 reference

23 November 2017

Hideki Onishi

7

1 reference

23 November 2017

Fusao Ikeda

8

1 reference

23 November 2017

Yasuhiro Miyake

9

1 reference

23 November 2017

Shinichiro Nakamura

10

1 reference

23 November 2017

Hidenori Shiraha

11

1 reference

23 November 2017

Akinobu Takaki

12

1 reference

23 November 2017

Shouta Iwadou

13

1 reference

23 November 2017

Yoshiyuki Kobayashi

14

1 reference

23 November 2017

Koichi Takaguchi

15

1 reference

23 November 2017

Yoshitaka Takuma

16

1 reference

23 November 2017

Hiroyuki Takabatake

17

1 reference

23 November 2017

Kohsaku Sakaguchi

18

1 reference

23 November 2017

Kazuhide Yamamoto

19

1 reference

23 November 2017

Okayama Liver Cancer Group

20

1 reference

23 November 2017

publication date

29 April 2013

1 reference

23 November 2017

1 reference

23 November 2017

volume

44

1 reference

23 November 2017

issue

3

1 reference

23 November 2017

page(s)

296-301

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12123

21 January 2018

Identifiers

DOI

10.1111/HEPR.12123

1 reference

23 November 2017

1 reference